Join Growin Stock Community!

Proqr therapeutics n.v.PRQR.US Overview

US StockHealthcare
(No presentation for PRQR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PRQR AI Insights

PRQR Overall Performance

PRQR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PRQR Recent Performance

-2.55%

Proqr therapeutics n.v.

0.05%

Avg of Sector

-0.31%

S&P500

PRQR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PRQR Key Information

PRQR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PRQR Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Price of PRQR

PRQR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PRQR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.40
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.42
PB Ratio
2.50
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-264.83%
Revenue Growth (YoY)
-24.60%
Profit Growth (YoY)
-24.60%
3-Year Revenue Growth
41.45%
3-Year Profit Growth
41.45%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.40
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.42
PB Ratio
2.50
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-264.83%
Revenue Growth (YoY)
-24.60%
Profit Growth (YoY)
-24.60%
3-Year Revenue Growth
41.45%
3-Year Profit Growth
41.45%

  • When is PRQR's latest earnings report released?

    The most recent financial report for Proqr therapeutics n.v. (PRQR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PRQR's short-term business performance and financial health. For the latest updates on PRQR's earnings releases, visit this page regularly.

  • What is the operating profit of PRQR?

    According to the latest financial report, Proqr therapeutics n.v. (PRQR) reported an Operating Profit of -11.28M with an Operating Margin of -387.1% this period, representing a decline of 29.46% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is PRQR's revenue growth?

    In the latest financial report, Proqr therapeutics n.v. (PRQR) announced revenue of 2.92M, with a Year-Over-Year growth rate of -26.78%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does PRQR have?

    As of the end of the reporting period, Proqr therapeutics n.v. (PRQR) had total debt of 16.49M, with a debt ratio of 0.13. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does PRQR have?

    At the end of the period, Proqr therapeutics n.v. (PRQR) held Total Cash and Cash Equivalents of 106.88M, accounting for 0.86 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does PRQR go with three margins increasing?

    In the latest report, Proqr therapeutics n.v. (PRQR) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -387.1%%, and net margin of -377.6%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess PRQR's profit trajectory and future growth potential.

  • What is the FCF of PRQR?

    Proqr therapeutics n.v. (PRQR)'s Free Cash Flow (FCF) for the period is -12.77M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 93.96% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.